School of Clinical and Experimental Medicine, College of Medicine and Dental Sciences, University of Birmingham, Edgbaston, Birmingham, UK.
J Neurol. 2010 Nov;257(Suppl 2):S262-7. doi: 10.1007/s00415-010-5716-z.
This narrative review examines the effects of drug therapy on the natural history of Parkinson's disease. In terms of modifying the underlying disease process, it is possible that immediate therapy, rather than deferred treatment, can have a positive effect on the underlying disease process. However, it is unlikely that drug therapy has changed mortality from the condition and there is no evidence that it can delay the onset of non-motor features such as dementia and falls. The beneficial effects of drug therapy on the motor symptoms of Parkinson's disease are unquestionable, but these are at the expense of short-term dopaminergic side effects, long-term motor complications, and impulse control disorders. Major questions remain regarding which initial therapeutic approach should be taken which may possibly be answered by the ongoing PD MED trial. The beneficial effects of drug therapy on the motor features of Parkinson's disease have had a fundamental impact on the suffering of patients. The mainstay of these therapies continues to be levodopa, although it is now used at lower doses than in the past and in combination with other drug classes.
这篇叙述性评论探讨了药物治疗对帕金森病自然史的影响。就改变潜在的疾病过程而言,即时治疗而不是延迟治疗可能对潜在的疾病过程产生积极影响。然而,药物治疗不太可能改变该疾病的死亡率,也没有证据表明它可以延缓痴呆和跌倒等非运动特征的发生。药物治疗对帕金森病运动症状的有益效果是毫无疑问的,但这是以短期多巴胺能副作用、长期运动并发症和冲动控制障碍为代价的。关于应该采取哪种初始治疗方法的重大问题仍然存在,这可能可以通过正在进行的 PD MED 试验来回答。药物治疗对帕金森病运动特征的有益效果对患者的痛苦产生了根本性的影响。这些疗法的主要手段仍然是左旋多巴,尽管它现在的用量低于过去,并且与其他药物类别联合使用。